These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 23485165)

  • 1. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.
    Bedard PL; Mook S; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ; Cardoso F
    Expert Opin Med Diagn; 2009 Mar; 3(2):193-205. PubMed ID: 23485165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
    Audeh W; Blumencranz L; Kling H; Trivedi H; Srkalovic G
    Acta Med Acad; 2019 Apr; 48(1):18-34. PubMed ID: 31264430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
    Ishitobi M; Goranova TE; Komoike Y; Motomura K; Koyama H; Glas AM; van Lienen E; Inaji H; Van't Veer LJ; Kato K
    Jpn J Clin Oncol; 2010 Jun; 40(6):508-12. PubMed ID: 20110242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
    Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
    Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.
    Slodkowska EA; Ross JS
    Expert Rev Mol Diagn; 2009 Jul; 9(5):417-22. PubMed ID: 19580427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence of MammaPrint array types in clinical trials and diagnostics.
    Beumer I; Witteveen A; Delahaye L; Wehkamp D; Snel M; Dreezen C; Zheng J; Floore A; Brink G; Chan B; Linn S; Bernards R; van 't Veer L; Glas A
    Breast Cancer Res Treat; 2016 Apr; 156(2):279-87. PubMed ID: 27002507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
    Kondo M; Hoshi SL; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2012 Jun; 133(2):759-68. PubMed ID: 22315134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis.
    Lyman GH; Kuderer NM
    Clin Breast Cancer; 2006 Dec; 7(5):372-9. PubMed ID: 17239261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of MammaPrint
    Beumer IJ; Persoon M; Witteveen A; Dreezen C; Chin SF; Sammut SJ; Snel M; Caldas C; Linn S; van 't Veer LJ; Bernards R; Glas AM
    Biomark Insights; 2016; 11():139-146. PubMed ID: 27980389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
    Mook S; Van't Veer LJ; Rutgers EJ; Piccart-Gebhart MJ; Cardoso F
    Cancer Genomics Proteomics; 2007; 4(3):147-55. PubMed ID: 17878518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.